Subscribe
Share
Share
Embed
Today we’ll review data on the high frequency of germline RUNX1 mutations in patients with acute myeloid leukemia, learn more about the development of an international prognostic score that predicts time to first treatment in CLL patients with early, asymptomatic disease, and explore the possibility of improving the activity of virus-directed immunotherapies against certain types of EBV tumors.
The Blood Podcast summarizes content recently published in Blood, the most cited peer-reviewed publication in the field of hematology.